| 20052 |
Galcanezumab |
Emgality® |
For the prophylaxis of migraine in adults who have at least four migraine days per month. |
Assessment process complete |
13th January 2021 |
 |
| - |
Gefitinib |
Iressa® |
For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR. |
Assessment process complete |
5th November 2010 |
|
| - |
Gemtuzumab ozogamicin |
Mylotarg® |
For combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive AML, except acute promyelocytic leukaemia. |
Assessment process complete |
4th July 2019 |
|
| 19043 |
Gilteritinib |
Xospata® |
For the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with an FLT3 mutation. |
Assessment process complete |
3rd March 2021 |
|
| 20041 |
Glasdegib |
Daurismo® |
In combination with LDAC (low-dose cytarabine), for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia in adult patients who are not candidates for standard induction chemotherapy. |
Rapid Review Complete |
9th October 2020 |
|
| - |
Glecaprevir/Pibrentasvir |
Maviret® |
For the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic GT1-6. |
Assessment process complete |
17th August 2017 |
|
| 25037 |
Glofitamab |
Columvi® |
Glofitamab in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT). |
Rapid Review Complete |
2nd July 2025 |
|
| 23055 |
Glofitamab |
Columvi® |
Glofitamab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. |
Rapid Review Complete |
3rd October 2023 |
|
| - |
Glucosamine sulfate |
Dona® |
For the treatment of oestoarthritis in the Irish Healthcare setting. |
Assessment process complete |
7th June 2009 |
|
| - |
Glycerol phenylbutyrate |
Ravicti® |
For use as adjunctive therapy for chronic management of adult and paediatric patients ≥2 months of age with urea cycle disorders (UCDs). |
Assessment process complete |
20th June 2018 |
|
| - |
Glycopyrronium bromide |
Seebri Breezhaler® |
As a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD). |
Assessment process complete |
17th August 2012 |
|
| - |
Glycopyrronium bromide |
Sialanar® |
For symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. |
Assessment process complete |
13th June 2017 |
|
| - |
Golimumab |
(Simponi®) |
For the treatment of moderate to severe rheumatoid arthritis. |
Assessment process complete |
11th May 2010 |
|
| - |
Golimumab |
Simponi® |
For the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments. |
Assessment process complete |
31st October 2013 |
|
| - |
Grass pollen allergen extract |
Oralair® |
For the treatment of allergic grass pollen rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms confirmed by a positive cutaneous test and/or a positive titre of the specific IgE to the grass pollen. |
Assessment process complete |
13th October 2011 |
|
| - |
Guanfacine hydrochloride |
Intuniv® |
For the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. It must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures. |
Assessment process complete |
18th December 2015 |
|
| - |
Guselkumab |
Tremfya® |
For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
Assessment process complete |
6th February 2018 |
|
| 20059 |
Guselkumab |
Tremfya® |
For the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. |
Assessment process complete |
17th February 2021 |
|
